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Abstract In this study, we expressed and purified the p53
mutant encoded by the His175 allele (p53His175) in a
baculovirus expression system in order to study the folding and
the DNA binding activity of the protein. A two-site ELISA
revealed that purified p53His175 protein preferentially displayed
a PAb1620 conformation, which appeared to be not sufficient to
interact specifically with DNA. The cryptic DNA binding
activity of this mutant was then investigated by electrophoretic
mobility shift assay in the presence of anti-p53 antibodies, and
shown to be refractory to significant activation by PAb421 (a
potent allosteric activator of wild-type p53’s DNA binding
activity). Nevertheless, p53His175 DNA binding was regulated
by antibodies targeting the N-terminal region of the protein.
Furthermore, while the protein preferentially displayed a
PAb1620 conformation, our data suggested the existence of an
equilibrium between at least two folding states of the protein
(PAb1620 and PAb240 conformations). A model rationalizing
the conformation, antibody-interacting ability and DNA binding
regulation potential of p53His175 is presented.
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1. Introduction
In human tumors, most of the mutations identi¢ed in the
tumor suppressor p53 protein are localized within the central
DNA binding domain. Strikingly, six residues within this re-
gion have been found to be preferentially targeted for muta-
tion (Arg175, Gly245, Arg248, Arg249, Arg273 and Arg282)
and correspond to 40% of all p53 mutations [1]. Analysis of
the co-crystal of the central DNA binding domain of p53 and
its cognate binding sequence has given great insight into how
mutations at these hotspots lead to abrogation of p53 se-
quence-speci¢c DNA binding [2]. The existence of these muta-
tional hotspots emphasizes the importance of the conforma-
tion and the sequence-speci¢c DNA binding in the normal
biological function of p53.
Anti-p53 monoclonal antibodies (mAbs) which interact
with the conformationally-£exible DNA binding domain of
p53 have been used to elucidate the global a¡ects of missense
mutations on the structure of p53’s core, and to permit the
de¢nitions of wild-type (wt) and mutant conformations of
p53. PAb240 and DO-12 antibodies are de¢ned as being
able to detect the mutant conformation of p53 [3^6]. These
two antibodies target respectively two di¡erent cryptic linear
epitopes within the conformationally £exible central core of
the molecule. These epitopes are only exposed upon denatu-
ration of the wild-type p53 (wt p53) protein, and are acces-
sible in a variable fraction of point-mutant p53 molecules
[4^6]. PAb1620 displays a reciprocal behavior, as it interacts
preferentially with native wt p53, fails to bind to denatured
protein, and precipitates none or a fraction of mutant p53
expressed in di¡erent cell lines [4,5,7^9]. However, the border
between these mutant and wild-type conformations is not
clearly de¢ned. Indeed, during formation of hetero-oligomers
with mutant proteins [10], during cell division [11,12], or when
bound to DNA [13], wt p53 can adopt the mutant conforma-
tion. In contrast, in cell lines expressing de¢ned p53 point
mutations, it appeared that PAb1620 was able to precipitate
a fraction of p53 mutant proteins, suggesting that the total
pool of the p53 mutant proteins encoded by the same allele
can contain complementary fractions of both PAb1620-posi-
tive/PAb240-negative molecules and PAb1620-negative/
PAb240-positive molecules. The proportion of these two
forms was found to vary greatly from mutation to mutation,
and from cell line to cell line [4^6,9]. These observations taken
together suggested the ease with which p53 proteins seem to
be able to adopt alternate conformations. The association of
these alternate conformations of p53 with di¡erent biological
activities led to the suggestion that such conformational
changes may be important for the normal regulation of p53
function.
In order to decipher the meaning of p53 mutation for tu-
mor suppression, a number of studies have characterized the
DNA binding and transactivation activities of tumor-derived
p53 mutants [14^16]. However, the majority of this work has
focused on the analysis of p53 protein derived from crude cell
lysates rather than biochemically pure entities. In this study,
we expressed and puri¢ed the p53 mutant protein encoded by
the His175 allele (p53His175) in a baculovirus expression sys-
tem. The conformation and the DNA binding activity of this
protein have been investigated by a two-site enzyme linked
immunosorbent assay (ELISA) and electrophoretic mobility
shift assay (EMSA), using a set of well-characterized anti-
p53 antibodies. These ¢ndings provide an opportunity for us
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to understand the regulation of the conformation and the
DNA binding properties of the most highly represented and
oncogenic p53 mutants in human neoplasia.
2. Materials and methods
2.1. Antibodies
Anti-p53 mAbs DO-2, DO-1, PAb1801, PAb241, PAb243, PAb421,
PAb122, PAb1620, PAb240, and DO-12 [3,4,17^21] were puri¢ed us-
ing protein A-Sepharose. CM1, a rabbit polyclonal antiserum, was
raised against recombinant human p53 [22]. DO-2 interacts with an
epitope on p53 comprising the amino acids (aa) 10^16 [23]; DO-1
recognizes aa 20^25 [23]; PAb1801 targets aa 46^55 [18]; 200.47 binds
aa 81^95 [24]; PAb241 and PAb243 [4] both recognize an epitope
corresponding to aa 296^305 on human p53 [22]; PAb421 [19] and
PAb122 antibodies [20] bind to a similar region on human p53 com-
prising aa 371^380 [23]; PAb240 recognizes a linear epitope within the
central core of p53, aa 212^217 [23]; DO-12 binds to another cryptic
linear epitope within p53’s core corresponding to aa 256^270 [21].
Production and characterization of the DO-1 single chain variable
fragment (scFv) is described elsewhere [25].
2.2. ELISA of wt p53 and p53His175 proteins
Human wt p53 and p53His175 were puri¢ed from recombinant
baculovirus infected Spodoptera frugiperda (Sf9) insect cells by previ-
ously described methods [26]. Mabs used for capture were ¢rst ad-
sorbed onto a 96-well PVC assay plate (Falcon) overnight at 4‡C (50
Wl, 10 Wg/ml in a phosphate-bu¡ered saline solution (PBS)). After
blocking in the presence of 5% (w/v) low fat milk powder and 0.1%
(v/v) Tween 20 (PBSMT), puri¢ed p53His175 or wt p53 were incu-
bated for 1 h at 4‡C (3 Wg/ml in a volume of 50 Wl in PBSMT).
Control wells contained only the capture monoclonals. After washing,
the rabbit anti-p53 serum CM1 was incubated for 2 h at 4‡C (50 Wl,
1/2000 in PBSMT). Subsequent to a ¢nal wash, p53-antibody com-
plexes were detected by a swine anti-rabbit horseradish peroxidase-
conjugated serum (Dako, Glostrup, Denmark). A Dynatech plate
reader was used to measure absorbance at 450 nm.
2.3. Transient transfection
The p53 null human lung carcinoma H1299 cells were maintained in
Dulbecco’s modi¢ed Eagle medium and supplemented with 10% fetal
calf serum at 37‡C. Cells were seeded 24 h before transfection to 70^
80% con£uence. Calcium phosphate mediated transfections were per-
formed as previously described [27]. Two micrograms of a plasmid
encoding the human p53His175 protein (pCMV-Neo-p53His175) was
transfected into a sub-con£uent 10 cm dish culture. Control trans-
fections were performed with 2 Wg of the pCMV-Neo-Bam vector
[28]. Forty-eight hours after transfection, cell lysates were prepared
[29] and tested in the two-site ELISA where PAb1620 or PAb240 were
used as the capture antibodies and CM1 was used for detection of
p53His175.
2.4. Electrophoretic mobility shift assay
Binding conditions using the speci¢c p53 consensus sequence (PG)
were as previously described [30]. Standard reactions were assembled
at 4‡C with 190 nM of Sf9-produced p53His175 mutant in presence of
330 nM of an anti-p53 mAb. The anti-Mdm2 (protein encoded by the
murine double minute gene 2) mAb 4B2 [31] was used as negative
control (330 nM). Characterization of the PAb1620 and PAb240 ac-
tivities of p53His175 (190 nM) in EMSA experiments was performed
by assembling reaction mixtures containing 460 nM of DO-1 with
various amounts of either PAb1620 or PAb240, details are given in
the ¢gure legends. Incubations were performed for 40 min on ice
before the DNA binding assay. Control experiments were carried
out by substituting p53His175 mutant with wt human p53 (10 nM).
3. Results
3.1. Puri¢ed p53His175 reveals a ‘wild-type conformation’ in
ELISA
A panel of mAbs that interact with an array of epitopes
between the N- and C-terminus of p53 was used to decipher
subtle di¡erences in epitope availability between wt p53 and
p53His175 in ELISA. The results (Fig. 1) revealed that each
of the targeted epitopes were equally available for binding
across both p53His175 and the wild-type protein. The data
suggested that point mutation at this site did not alter the
structure of the mutant p53 su⁄ciently to make a series of
linear epitope determinants across the molecule di¡erently ac-
cessible to wt p53.
The p53His175 was predicted to be a denaturing or unfold-
ing mutation [32], and previous analysis of p53His175 pro-
teins in immunoprecipitation assays from tumor cell lysates
revealed that the majority of the protein adopted a PAb1620-
negative/PAb240-positive/DO-12-positive conformation
[21,33]. When tested in ELISA, the majority of the
p53His175 protein was strikingly seen to mainly adopt a
PAb1620 rather than a PAb240 or a DO-12 conformation,
similarly to the wt protein (Fig. 1). As the conformation of
the p53His175 might be a consequence of a peculiarity of the
Sf9 cell type, we analyzed the conformational status of
p53His175 expressed in null human lung carcinoma H1299
cells. The results (Fig. 2) showed that H1299-derived
p53His175 contained in equal proportion a pool of
PAb1620-positive proteins as well as a pool of PAb240-pos-
itive proteins. In contrast, the majority of Sf9-derived
p53His175 mainly adopted, as said above, a PAb1620 confor-
mation. Taken together, these data suggested the point muta-
tion ArgCHis at the codon 175 does not always signi¢cantly
unfold the structure as de¢ned by classic PAb240-positive/
PAb1620-negative reactivity, as the p53His175 protein was
able to adopt the PAb1620 conformation in two independent
cell lines.
3.2. N-terminal regulation of the cryptic DNA binding activity
of the p53His175 mutant
The ‘wild-type’ PAb1620 conformation of p53 has been
previously described as being a pre-requisite for sequence-spe-
ci¢c DNA binding [34]. When an EMSA was performed on
p53His175 puri¢ed fractions, the results demonstrated this
point mutant possessed a very weak and unstable innate abil-
Fig. 1. Epitope analysis of Sf9-derived p53His175 and wt p53. The
anti-p53 mAbs were independently immobilized in ELISA wells and
then incubated with either p53His175 (50 Wl, 3 Wg/ml) black column,
or, wt p53 (50 Wl, 3 Wg/ml) white column. Binding was compared
with a bu¡er control (gray column). Detection of p53-antibody
complexes was performed with the polyclonal serum CM1.
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ity to interact with DNA, as observed by Friedlander and
colleagues [35] (Fig. 3, lane 1). These ¢ndings suggest that,
at least for this particular mutant, the PAb1620 conformation
cannot be considered as a su⁄cient condition for DNA bind-
ing.
In order to explore the regulation of the cryptic DNA bind-
ing function of p53His175, we tested a panel of anti-p53
mAbs in EMSA experiments. The C-terminal speci¢c mAbs,
PAb421 and PAb122, have previously been shown to greatly
activate the latent DNA binding activity of wt p53 [13,30] and
the point mutants p53Lys285 and p53His273 [36]. As illus-
trated in Fig. 3, neither PAb421 (lane 8), nor PAb122 (lane
9) demonstrated any ability to activate the DNA binding ac-
tivity of p53His175. Similarly, no visible e¡ect was observed
in the presence of Pab241 (lane 6), Pab243 (lane 7), PAb1620
(lane 11), PAb240 (lane 12), DO-12 (lane 13), 200.47 (lane 14),
or an irrelevant anti-Mdm2 antibody (lane 10). On the con-
trary, the N-terminal speci¢c mAbs, DO-2, DO-1, and
PAb1801, were demonstrated to greatly enhance p53His175’s
DNA binding activity (lanes 2, 3 and 5, respectively). As the
p53 tetrameric state is essential for the DNA binding activity
of wt p53 [26], we sought to determine what e¡ect bivalence
and size played upon the activating potential of N-terminal
speci¢c mAb interaction with p53His175 by performing the
assay in the presence of the DO-1 scFv [25]. As illustrated in
Fig. 3, lane 4, the DO-1 scFv was also able to enhance the
DNA binding activity of p53His175.
Taken together, these results suggested that the C-terminal
region of this mutant does not negatively regulate the DNA
binding activity of the protein as it does for wt p53 or other
mutant p53 proteins [13,30,36]; in contrast, the binding of
even a small molecule to the N-terminus of the p53His175
Fig. 2. Quantitative analysis of the PAb1620/PAb240 conformation-
al status of p53His175 in Sf9 and H1299 cell lines. The Sf9- and
H1299-expressed p53His175 proteins were tested in a two-site ELI-
SA using either PAb1620 or PAb240 as capture mAbs. Results were
expressed as the ratio of the PAb240-capture signal and the
PAb1620-capture signal (OD450 nmPAb240/OD450 nmPAb1620 ratio).
These data represent the mean of three independent experiments,
the error bars represent the standard error of the mean.
Fig. 3. DNA binding activity of the p53His175 protein. EMSA
demonstrating the interaction of latent p53His175 (190 nM) with
DNA after incubation (30 min at 4‡C) alone (lane 1), or in presence
of a panel of anti-p53 mAbs (300 nM): DO-2 (lane 2), DO-1 (lane
3), PAb1801 (lane 5), PAb241 (lane 6), PAb243 (lane 7), PAb421
(lane 8), PAb122 (lane 9), PAb1620 (lane 11), PAb240 (lane 12),
DO-12 (lane 13) and 200.47 (lane 14). The anti-Mdm2 mAb 4B2
was used as a negative control (lane 10). DO-1 scFv (500 nM) was
tested on lane 4.
Fig. 4. The DNA binding activity of DO-1-p53His175 is inhibited
by PAb1620 interaction. EMSA demonstrating inhibition of DNA
binding of DO-1-activated p53His175 by PAb1620. p53His175 (190
nM) (A), or wt p53 (10 nM) (B), were assembled alone (lane 1),
with 460 nM of DO-1 (lane 2), with 530 nM of PAb1620 (lane 3),
or in presence of a DO-1 reaction (460 nM) containing decreasing
amounts of PAb1620 (530 nM, 180 nM, and 60 nM) (lanes 4^6).
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mutant induces a conformational change in the protein, there-
by allowing sequence-speci¢c DNA binding, and de¢ning a
new allosteric regulatory domain for this particular mutant.
3.3. Probing the PAb1620/PAb240 conformation of the
p53His175 mutant by destabilization of DO-1-p53His175-
DNA complexes
Given the fact that p53His175 appeared to have a distinct
method for allosteric activation to wt p53, we wondered
whether the accessibility of the conformationally sensitive
antibody epitopes targeted by PAb1620 and PAb240 in the
DNA binding conformation would be di¡erent to the wt pro-
tein. As illustrated in Fig. 4A, DNA binding assays performed
in the presence of DO-1-activated p53His175 and an increas-
ing amount of PAb1620 showed a dramatic reduction in the
amount of p53His175-DNA complex formation (lanes 4^6
versus lane 2). In contrast, PAb1620 did not interfere with
the formation of wt p53-DNA complexes (Fig. 4B). Due to
the di¡erence in speci¢c DNA binding activity, wt p53 was
used at a 20 times less concentration than p53His175 in these
assays. Similar experiments carried out with PAb240 revealed
that this antibody behaved surprisingly similarly to PAb1620.
The increasing amounts of PAb240 which were incubated in
the presence of DO-1 activated p53His175 led to reduced
formation of p53His175-DNA complexes (Fig. 5A, lanes 4^6
versus lane 2). In contrast, the extent of wt p53-DNA complex
formation was una¡ected by PAb240 (Fig. 5B). The e¡ect of
PAb1620 and PAb240 on p53His175’s DNA binding activity
was speci¢c, as the assay was performed in the presence of
excess of non-speci¢c protein (bovine serum albumin, 1 mg/
ml), and as this phenomenon was not observed when another
antibody such as PAb421 was tested (data not shown). These
observations suggested that PAb1620 and PAb240 interaction
with p53His175 locks the conformation of the latter into one
that is inactive for DNA binding and resistant to N-terminal
regulation of the molecule by N-terminal speci¢c antibodies.
The e¡ect of PAb240 in these EMSA experiments was unex-
pected, as the p53His175 proteins were found by ELISA
mostly in a PAb1620 conformation (Figs. 1 and 2). However,
these results were not contradictory, as the EMSA is a more
sensitive assay than the ELISA to detect weak proteinic inter-
actions. Taken together, these data suggested the existence of
an equilibrium between the PAb240 and the PAb1620 confor-
mations of p53His175, while the latter was the preferred one.
These observations also suggested that the DNA binding ac-
tivation of p53His175 by N-terminal antibodies is a weak
process (easily destabilized by PAb1620 and PAb240 interac-
tion). This was reinforced by the comparison of the intens-
ity of the DNA binding signals obtained with wt p53 and the
DO-1-activated p53His175. Indeed, even when the p53His175
protein tested was 20 times more concentrated than wt p53 in
the EMSA experiments (190 nM versus 10 nM), the signal
obtained for the DNA binding of DO-1-activated mutant
was still weaker than for wt p53 (compare lanes 2 in Fig.
4A,B, or in Fig. 5A,B).
4. Discussion
This report has allowed a more detailed understanding of
the conformational states in which the p53His175 protein can
reside. Our data suggested that this mutation does not spon-
taneously unfold the protein, as de¢ned by PAb1620 immu-
noreactivity, when the protein was expressed in two di¡erent
cell lines. Previous predictions have suggested that refolding
of mutant p53’s into the PAb1620-conformation may restore
Fig. 5. The DNA binding activity of DO-1-p53His175 is destabilized
by PAb240 interaction. EMSA demonstrating inhibition of DNA
binding of DO-1-activated p53His175 by PAb240. p53His175 (190
nM) (A), or wt p53 (10 nM) (B), were assembled alone (lane 1),
with 460 nM of DO-1 (lane 2), with 530 nM of PAb240 (lane 3), or
in presence of a DO-1 reaction (460 nM) containing decreasing
amounts of PAb240 (460 nM, 150 nM, and 50 nM) (lanes 4^6).
Fig. 6. Conformational £exibility of the p53His175 mutant protein.
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function to the protein. However, our data indicated that
acquisition of the ‘folded’ conformation to p53His175 does
not restore sequence-speci¢c DNA binding and reveals a yet
unde¢ned structural defect within the core domain. Investiga-
tion of the cryptic DNA binding activity of the p53His175
mutant suggested that the C-terminal region of the protein
does not appear to be an allosteric regulatory domain as it
does for wt p53 [13,30,36].
The amino terminus of p53 harbors the transactivation do-
main that drives p53-dependent transcription [37], and ap-
peared also to allosterically regulate core DNA binding activ-
ity. The ¢rst clear evidence for this came from the observation
that Mdm2-p53 complexes synthesized in vivo are inherently
inactive for DNA binding, suggesting Mdm2 protein can dis-
tort the core DNA binding domain through conformational
alterations [38]. The ability of the N-terminal antibody DO-1
to stimulate CK2-modi¢ed or HSP70-modi¢ed mutant p53
proteins [36], also suggest that the N-terminus contains regu-
latory domains that can e¡ect core DNA binding activity.
Furthermore, modi¢cation of the N-terminus of p53 protein
by mAbs can protect the DNA binding activity of wt and
mutant forms of p53 protein from thermal denaturation
[35,39].
Our results demonstrated that the ArgCHis point muta-
tion of p53 did not lock the protein in a state that is refractory
to DNA binding. Rather (Fig. 6), the protein exists in an
equilibrium between di¡erent DNA binding conformations,
with the inactive state being the preferred one. Factors (like
mAbs) interacting with a N-terminal regulatory domain of the
protein can stimulate the weak DNA binding function of this
mutant, and reverse, at least for a population of the
p53His175 proteins, the conformation of molecule into one
active for DNA binding. The process of DNA binding acti-
vation of the p53His175 protein by N-terminus speci¢c mol-
ecules was shown to be weak, as easily destabilized by
PAb1620 and PAb240 antibodies. These results demonstrated
that the His175 mutation revealed a new equilibrium between
the PAb240 and the PAb1620 conformations. The PAb1620
conformation was the exacerbated one detected in the Sf9-
produced p53His175 proteins, while when expressed in an
other cell line (H1299), an equal proportion of PAb1620
and PAb240 fractions was detected (Fig. 2). As temperature
was shown in vitro to a¡ect the PAb1620 conformation of wt
p53 [39], the di¡erence in the proportion of PAb1620 and
PAb240 populations of the p53His175 mutant expressed in
the Sf9 and H1299 cell lines may re£ect the di¡erence of
temperature at which the cells were grown (22‡C and 37‡C,
respectively), as well as possible interactions of the p53His175
mutant with speci¢c cellular factors in£uencing the folding
state of the protein.
Taken together, our data suggested the £exibility of the
p53His175 mutant to adopt di¡erent conformational states.
This was in agreement with the work from Bullock and col-
leagues [40] who investigated thermodynamic stability of wild-
type and mutant p53 core domains. The results of this study
demonstrated that di¡erent p53 mutant core domains (includ-
ing the p53His175 one), while less stable than the wild-type,
are not locked in an unfolded state, but do retain cooperative
conformational states. Moreover, it has recently been shown
that the DNA binding activity of wt p53 can be modulated via
the conformational equilibrium between the wt and the mu-
tant states of the protein [41]. Current work is geared into
developing probes that can dissect in vivo the sites of struc-
tural change within the p53His175 protein, in order to under-
stand the regulation of the conformation and the DNA bind-
ing properties of the most highly represented and oncogenic
p53 mutants in human neoplasia.
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